Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2024 –2031 | |
|
|
USD 2.51 Billion |
| USD 4.68 Billion | |
| % | |
|
The Global Pneumonia Therapeutics Market size in 2023 is USD 2.51 billion. The market share is projected to grow at a CAGR of 8.10% and reach USD 4.68 billion by 2031.
Get Exclusive Sample Copy of this Report Here
The global pneumonia therapeutics market is expected to grow significantly, owing predominantly to the increasing incidence of pneumonia worldwide, with a particularly strong impact in low- and middle-income countries with less solid healthcare infrastructure. Pneumonia continues to be a prominent cause of death among vulnerable groups, particularly children under the age of five, According to WHO Pneumonia killed 740180 children under the age of 5 in 2019, accounting for 14% of all deaths of children under 5 years old, highlighting the urgent need for more effective treatments and preventive measures. Rising antibiotic resistance, particularly against common infections like Streptococcus pneumoniae, is a major driver of demand for innovative medicines such as next-generation antibiotics, improved vaccines, and supportive care methods.
Data Bridge Market Research Market Report provides details of new recent developments, market share, market trends on the basis of its segmentations and regional analysis, the impact of market players, analyses of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.
|
Global Pneumonia Therapeutics Report Metric Details
|
|
||
|
Report Metric
|
Details
|
||
|
Forecast Period
|
2024-2032
|
||
|
Base Year
|
2024
|
||
|
Historic Year
|
2023 (Customizable 2016-2021)
|
||
|
Measuring Unit
|
USD Billion
|
||
|
Data Pointers
|
Market value, growth rate, market segments, geographical coverage, market players, and market scenario, in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
||
The global pneumonia therapeutics market is also witnessing increased investment in research and development to combat the growing threat of multidrug-resistant strains of Streptococcus pneumonia. Furthermore, the introduction of newer vaccines, such as the Pneumococcal Conjugate Vaccine (PCV), and advancements in antiviral medications are playing a critical role in mitigating the global pneumonia therapeutics market growth. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Pneumonia Therapeutics Market is increasing at a CAGR of 8.10%. Our detailed analysis forecasts that the market is valued at USD 2.51 billion in 2023 and is expected to grow upto USD 4.68 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.
Global Pneumonia Therapeutics Market Dynamics
Increase in pneumonia Cases
The rising prevalence of pneumonia, particularly among vulnerable populations such as children under five and the elderly, is a primary driver of the global pneumonia therapeutics market. According to the World Health Organization (WHO), pneumonia causes 14% of all child fatalities under the age of five, killing roughly 740,180 children each year. Such worrisome trend emphasizes the critical need for improved treatments and prevention strategies.
Antibiotic Resistance
Centers for Disease Control and Prevention (CDC) reports that in the United States alone, about 30% of Streptococcus pneumoniae infections are resistant to one or more clinically relevant antibiotics. Antibiotic resistance, particularly in strains for instance, Streptococcus pneumoniae, is a critical challenge driving the need for new antibiotics and combination therapies in the pneumonia therapeutics market. Consequently, the urgent need to combat such resistant strains has spurred significant investment in the research and development of novel antibiotics, as well as combination therapies
Growing number of on-going clinical trials for the development of drug molecules will have a major impact on the market progression. For instance, According to WHO, in 2022 global clinical trial activity remained strong despite the COVID-19 pandemic. Non-COVID trial activity increased by 8% from 2019 to 2022. The expansion of clinical research not only accelerates the development of breakthrough treatments but also stimulates investment and fosters collaboration across the healthcare sector, thereby propelling the overall growth of the pneumonia therapeutics market.
Government and healthcare initiatives
Government and healthcare initiatives, including expanded immunization programs and improved healthcare access, significantly support the growth of the global pneumonia therapeutics market. for instance, U.S. Healthy People 2030 objectives, aim to improve access to preventive and therapeutic services for pneumonia, further enhancing market growth.
High Cost of Therapy
The high cost of advanced pneumonia therapies, such as novel antibiotics and biologics, presents a significant challenge to market growth. For instance, the development of new antibiotics can cost upwards of $1.5 billion, considering the extensive research, clinical trials, and regulatory processes involved. Similarly, biologics, which include monoclonal antibodies and other specialized treatments, can have development costs exceeding $2 billion. Financial barrier's limits the ability of these regions to procure and administer advanced treatments, impacting overall pneumonia management and hindering market expansion.
Lack of technical skills.
Limited healthcare infrastructure in low- and middle-income regions severely impacts pneumonia management and market growth. For instance, According to WHO the share of health in government spending increased over the past two decades in upper-middle and high income countries, stagnated in lower-middle income countries and declined in low income countries between 2000 and 2011. Consequently, the inability to provide timely and appropriate care in lower-middle income countries not only affects patient outcomes but also hinders the overall growth of the pneumonia therapeutics market.
Regulatory and market approval hurdles
The approval process for new therapies is both rigorous and time-consuming, requiring extensive Navigating regulatory and market clearance hurdles is a major problem in the pneumonia therapeutics market, frequently resulting in delays and increased costs for novel medicines. For instance, the antibiotic Ceftaroline required a lengthy approval process from the United States Food and Drug Administration (FDA) due to rigorous evaluation of clinical trial data and manufacturing practices. Such lengthy and costly approval processes not only add to pharmaceutical companies' financial burdens, but also delay the introduction of potentially life-saving pneumonia medicines to the market, impacting patient access and overall market growth.
|
Global Pneumonia Therapeutics Market Segmentations Overview
|
|
|
Market
|
Sub-Segments
|
|
Infection Type
|
Hospital-acquired Pneumonia (HAP), Community-acquired Pneumonia (CAP), Ventilator-associated Pneumonia (VAP)
|
|
Drug Class
|
Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs
|
|
Age Group
|
Pediatric, Adult, Geriatric
|
|
Type
|
Drugs, Preventive Vaccines, Oxygen Therapy
|
|
Route of Administration
|
Oral, Parenteral, Others
|
|
End-Users
|
Hospitals, Homecare, Specialty Clinics, Others
|
|
Distribution Channel
|
Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
|
|
Global Pneumonia Therapeutics Market Regional Overview
|
|
|
|
Region
|
Countries
|
|
|
Europe
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe
|
|
|
APAC
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
|
North America
|
U.S., Canada, and Mexico
|
|
|
MEA
|
Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East, and Africa
|
|
|
South America
|
Brazil, Argentina, and Rest of South America
|
|
Key Insights
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.